Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices’ small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA). The grant will fund approximately 66% of a NIS 1.23 million ($373,000) project aimed at acquiring and installing an advanced fill-and-finish system for sterile manufacturing. This investment addresses a major industry gap, as most early-stage biotech companies in Israel lack access to local, flexible, small-scale GMP manufacturing. As a result, many are forced to outsource overseas at high cost, with long lead times and limited control. Designed to accommodate diverse primary packaging formats with minimal reconfiguration, the system enables rapid batch turnaround and efficient switching between campaigns, substantially enhancing Scinai’s fill-and-finish capacity and operational flexibility.
Strengthening Scinai’s CDMO Infrastructure
The IIA’s decision recognizes Scinai’s leadership in building Israel’s biopharma manufacturing infrastructure. As noted in the Israel Innovation Authority’s award letter, CDMO services are essential for early-stage pharmaceutical and academic teams, allowing them to make the most of limited resources by accessing advanced facilities, equipment, and expertise without major capital investment.
Although Israel’s biopharma sector, with over 300 companies, remains underserved by a full-service CDMO, the same challenge exists globally among early-stage biotech innovators. Scinai is addressing this need by offering end-to-end, flexible CDMO solutions to clients in Israel, the U.S., and Europe, supporting drug development from early clone selection through GMP drug substance and drug product manufacturing.
Since initiating CDMO operations in 2023, Scinai Bioservices has provided high-quality manufacturing and development support to numerous Israeli and international biotech companies. The Jerusalem-based cGMP facility offers close collaboration, rapid project initiation, and flexible technical execution, delivering personalized attention that early-stage clients value. The planned expansion supported by the IIA grant will further strengthen Scinai’s ability to provide agile, small-batch, end-to-end CDMO services to biotech innovators in Israel and worldwide, fully compliant with EMA and FDA cGMP standards.
“This grant is a strong vote of confidence in Scinai Bioservices’ growing role as a cornerstone of Israel’s biopharma manufacturing ecosystem,” said Amir Reichman, CEO of Scinai. “The IIA’s support enables us to expand our fill-and-finish capacity and provide early-stage biotech companies in Israel and abroad with the kind of flexible, high-quality, and responsive CDMO partnership typically available only through large global players. We’re proud to deliver these capabilities locally—combining world-class standards with the personalized attention that early-stage innovators deserve”.
Serving Early-Stage Biotech Clients Worldwide
Scinai Bioservices focuses on supporting early-stage biotech companies in Israel, the U.S., and Europe that require personalized, agile, and cost-effective solutions. These projects—often funded by venture investors or biotech entrepreneurs—value immediate project starts, hands-on technical guidance, and close scientific collaboration, which larger CDMOs rarely provide as they prioritize major pharma accounts. Scinai delivers this boutique approach at competitive prices while maintaining global regulatory compliance.
Installation and qualification of the new filling system are expected in Q1 2026, with commercial operation planned for Q2 2026.
Scinai’s Complementary R&D Business
In addition to its CDMO operations, Scinai’s R&D business unit develops novel biological drug candidates for inflammatory and immunological (I&I) diseases. The Company holds an option to acquire PinCell Srl, developer of PC111 for severe autoimmune blistering diseases such as pemphigus vulgaris (PV), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Scinai is also advancing an intradermal NanoAb targeting IL-17 A and F for localized treatment of plaque psoriasis, and it retains exclusive options to in-license additional NanoAbs from the Max Planck Society (MPG) and University Medical Center Göttingen (UMG) addressing I&I indications with unmet medical needs.
